Enter Forcyte Bio: Cell function is the epicenter of disease and its treatment, and the ultimate goal of all therapeutics is to affect cell function. At Forcyte, our approach is to confront cell function at the outset of drug discovery, at the earliest stages to dramatically improve the odds of successful translation. Our philosophy is to […]
LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), and others. Including public support, this funding brings Forcyte’s total raised to $5.7M for their internal “mechano-therapeutic” pipeline, focusing first on fibrosis. “Contractile cell function
Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis
Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force plays a big role. These tools will enable researchers to get to functional endpoints faster, using human cells, but without using humans. 384-wellplate products will
The collaborative App Note can be requested directly from Molecular Devices. Inquiries may be directed to firstname.lastname@example.org. Free assay samples are available! Download App Note Here!
Forcyte has been selected as 1 of 8 companies given a presentation space at the Society of Laboratory Automation and Screening annual meeting in Washington D.C. on Feb 4-6. We will be showcasing our functional contractility assay technology, discussing ideas, seeking collaboration opportunities and learning about other evolving fields and challenges. Come by our booth!
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on uterine contractility that will enable deeper functional studies on reproductive disorders.
Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on vasodilation triggers of migraine pain that will enable rapid phenotypic screening for cranial vasoprotectors.
We are seeking a razor-sharp and self-driven ‘A-player’ trained in and stimulated by biotechnology to join the founding team and lead operations in our LA Biomed location! Great opportunity to become a part of something special early on and grow with the company. Let your colleagues know! Link to job ad: https://forcytebio.com/wp-content/uploads/2018/03/Associate-Bioengineer-short.pdf Get in touch
>3 years of work and development in the Di Carlo Lab has led to a thorough publication describing the broad capabilities and use-cases for the FLECS platform. On February 8, 2018, our paper “Elastomeric sensor surfaces for high-throughput single-cell force cytometry” was published online in Nature Biomedical Engineering! Link: https://www.nature.com/articles/s41551-018-0193-2 Thanks to all who contributed